Skip to main content

People in the News: Shaun McMeans; Timothy Holtzer; Sam Rua; David Martyr; Thomas Bachmann; Gerard Vaillant

Premium

HTG Molecular has made several new appointments to its executive team. Shaun McMeans has been named vice president of finance, administration, and chief technology officer; Timothy Holtzer has been named vice president of clinical diagnostic development; and Sam Rua has been named vice president of regulatory affairs and quality systems.

McMeans previously was CEO of Securaplane Technologies. Holtzer held various positions related to diagnostics at DiagnoCure, Centocor, and Abbott Laboratories. Rua was formerly vice president of global regulatory and clinical affairs at Beckman Coulter.


David Martyr has been named CEO of Tecan. The Swiss tools vendor said that Martyr will join the firm no later than Oct. 8, 2012, after he fulfills his contractual obligations to Danaher, where he is group executive and vice president. He previously was president of Leica Microsystems until Danaher acquired that firm in 2009.

Martyr succeeds Thomas Bachmann, who had held the position since 2005 and has left the firm. Board member Gerard Vaillant will serve as acting CEO until Martyr is ready to run the firm.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.